LANTERN PHARMA INC (LTRN) Stock News

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company dedicated to rebalancing inflammation for improved health outcomes, has successfully closed a public offering, raising approximately $4 million in gross proceeds. The offering included 3,640,000 shares of common stock (or equivalents) and warrants to purchase up to 14,560,000 shares, all priced at $1.10 per share and […]

Mentions: REVB ESLT CTKB KROS ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

S&P Global Ratings has downgraded its ratings on Varex Imaging Corporation (NASDAQ:VREX) because it believes the stock is surrounded by high levels of unpredictability and weaker credit metrics. Tariff drama has been lingering for quite some time now, and with uncertainty around policy implementation by the U.S. administration, the firm believes Varex’s profitability and sales […]

Mentions: VREX CTKB KROS CADL ...

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Lantern Pharma's Earnings Outlook

Preview: Lantern Pharma's Earnings

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lantern Pharma (NASDAQ:LTRN) just reported results for the second quarter of 20...

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024.

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284